Calcineurin inhibitors can cause glucose intolerance and lead to diabetes by reducing insulin secretion and increasing insulin resistance.[13] Therefore, regular diabetes risk assessment and screening are essential during glucocorticoid and calcineurin inhibitor therapy, regardless of the prescribed dose. This evidence concerns the gene INS and diabetes mellitus.